Dosing Schedule For Solvay’s Pulzium Will Be Addressed During Cardio-Renal Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Cardiovascular and Renal Drugs Advisory Committee also will weigh whether tedisamil should be approved with risk management plan proposed by Solvay.
You may also be interested in...
Astellas/Cardiome’s Vernakalant Wins Advisory Committee Approval In 6-2 Vote
Antiarrhythmic’s well-characterized safety profile is a “clear differentiator from other pharmacological therapies,” Astellas exec tells “The Pink Sheet” DAILY.
Astellas/Cardiome’s Vernakalant Wins Advisory Committee Approval In 6-2 Vote
Antiarrhythmic’s well-characterized safety profile is a “clear differentiator from other pharmacological therapies,” Astellas exec tells “The Pink Sheet” DAILY.
Astellas Pharma’s Vernakalant For Atrial Fibrillation Goes Before FDA Panel
FDA’s Cardiovascular and Renal Drugs Advisory Committee considers Astellas’ NDA re-submission for the indication Dec. 11.